3 coronavirus stocks poised to soar in 2021

They're risky but could deliver huge returns in the new year.

| More on:
coronavirus stocks represented by vaccine vials alongside piles of cash

Image source: Getty Images

You’re reading a free article with opinions that may differ from The Motley Fool’s Premium Investing Services. Become a Motley Fool member today to get instant access to our top analyst recommendations, in-depth research, investing resources, and more. Learn More

This article was originally published on Fool.com. All figures quoted in US dollars unless otherwise stated.

Sure, 2020 will forever be known as the year of the COVID-19 pandemic. But 2021 just might be memorialized as the year the pandemic was defeated. Two COVID-19 vaccines have already received emergency use authorization (EUA) in the United States with a third vaccine also authorized in the United Kingdom.

The big stories in the new year, though, could come from vaccines that haven't made it to market yet. It's possible that the stocks of the companies developing these experimental vaccines will deliver tremendous gains over the next 12 months. Here are three coronavirus stocks that are especially poised to soar in 2021.

1. Novavax

Novavax Inc (NASDAQ: NVAX) ranked as the top-performing coronavirus stock of 2020 with a staggering gain of close to 3,000%. Can the biotech stock deliver another sizzling performance this year? Don't be surprised if it happens.

The company expects to report results from a late-stage study of COVID-19 vaccine candidate NVX-CoV2373 conducted in the UK in early 2021. Novavax initiated another late-stage study in the US and Mexico last week. Look for results from this study sometime in the second quarter. 

If all goes well with these studies, billions of dollars will pour into Novavax's coffers. The company has deals in place with several countries (including the US, UK, Australia, Canada, and New Zealand) to supply close to 300 million doses of NVX-CoV2373. 

This cash influx will help Novavax further explore the development of a COVID-19/flu combo vaccine. The biotech already has a promising flu vaccine candidate called NanoFlu that's on track for regulatory submissions. 

2. Vaxart

Vaxart Inc (NASDAQ: VXRT) trailed behind only Novavax to become the No. 2 coronavirus stock of last year. It generated a sizzling return of around 1,600%. At one point in 2020, Vaxart's shares were up more than 4,700% year to date. I think the stock could have a lot more room to run in 2021.

The company is currently evaluating its COVID-19 vaccine candidate VXA-CoV2-1 in a phase 1 clinical study. Results from the study are expected this month. Vaxart hopes to quickly advance its experimental vaccine into phase 2 testing if the phase 1 results are positive.

VXA-CoV2-1 stands out from the leading coronavirus vaccines. It's a single-dose tablet instead of an injection. That makes Vaxart's vaccine more convenient to take and to distribute and store. The experimental vaccine also appears to promote mucosal immunity (immune system responses that occur in mucosal membranes in the eyes, nose, and elsewhere). 

Despite its impressive performance last year, Vaxart's market capitalisation remains below $700 million. With the advantages offered by VXA-CoV2-1, the biotech will be worth a lot more than that if its clinical studies of the COVID-19 vaccine candidate go well.

3. Altimmune

Altimmune Inc (NASDAQ: ALT) finished 2020 with its shares up close to 500%. By late July, the stock has soared more than 1,600% year to date. It's possible that Altimmune could regain those highs this year.

The biotech's COVID-19 vaccine candidate AdCOVID shares several things in common with Vaxart's experimental vaccine. It only requires a single dose. It can be stored at room temperature for extended periods. And it appears to provide mucosal immunity. The major twist is that AdCOVID is an intranasal vaccine.

There's one glaring problem for Altimmune right now, though. The US Food and Drug Administration (FDA) placed a clinical hold on a planned early stage clinical study of AdCOVID because it wants changes to the study's protocols and additional manufacturing data.

I suspect that Altimmune will be able to quickly address the FDA's concerns and move forward with its study of AdCOVID. The company even stated that it doesn't expect the clinical hold will significantly change its overall timeline for the development of the vaccine. If AdCOVID delivers on its potential, Altimmune could be an under-the-radar COVID vaccine stock that skyrockets in 2021.

Remember the risks

Keep in mind that all three of these stocks are very risky. While their experimental COVID-19 vaccines look promising right now, there's always a chance that they'll disappoint in clinical testing. Novavax, Vaxart, and Altimmune are poised to soar in 2021, but they could easily sink instead. 

This article was originally published on Fool.com. All figures quoted in US dollars unless otherwise stated.

Keith Speights has no position in any of the stocks mentioned. The Motley Fool Australia has no position in any of the stocks mentioned. The Motley Fool has a disclosure policy. This article contains general investment advice only (under AFSL 400691). Authorised by Bruce Jackson.

More on International Stock News

A male party goer sits wearing a party hat and with a party blower in his mouth amid a bunch of balloons with a sad, serious look on his face as though the party is over or a celebration has fallen flat.
International Stock News

What snapped the S&P 500 winning streak last night?

The S&P 500 almost made October a winner, but fell at the final hurdle.

Read more »

Man going down a red arrow, symbolising a sliding share price.
International Stock News

Why Nvidia stock is sinking today

Investors were spooked by economic data and the ambitions of a deep-pocketed rival.

Read more »

Rede arrow on a stock market chart going down.
International Stock News

Why Microsoft stock is sinking today

Microsoft just beat quarterly earnings estimates. So why is the stock falling?

Read more »

US economy and sharemarket with piggy bank
Share Market News

Here's why Goldman Sachs sees a decade of lower returns ahead for US shares

Aussie investors have placed a lot of faith in US shares this year.

Read more »

ETF written in gold with dollar signs on coin.
ETFs

Here's why the iShares S&P 500 ETF (IVV) flew 6% higher in October

Investors are very keen on US shares at the moment.

Read more »

Man pumping petrol
International Stock News

Where will Tesla shares be in 10 years?

This historically booming stock might not live up to the hype.

Read more »

A woman sits at her computer with her hand to her mouth and a contemplative smile on her face as she reads about the performance of Allkem shares on her computer
International Stock News

46% of Nvidia's revenue came from 4 mystery customers last quarter

Nvidia's incredible growth is increasingly reliant on just a handful of customers.

Read more »

A young girl looks up and balances a pencil on her nose, while thinking about a decision she has to make.
International Stock News

Should you buy Nvidia stock before November 20?

History could repeat itself with Nvidia's upcoming quarterly update.

Read more »